PERIODONTITIS AND VASCULAR DYSFUNCTION
Launched by UNIVERSITY COLLEGE, LONDON · Mar 1, 2017
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Participants must be ≥ 18 years-old.
- • 2. Participants must have moderate to severe periodontitis (at least 30 periodontal pockets \> 4mm with Bleeding on Probing) and radiographic signs of bone loss.
- • 3. Participants must have voluntarily signed the informed consent.
- Exclusion Criteria:
- • 1. Female participant is pregnant or lactating or of childbearing and not using acceptable methods of birth control.
- • 2. Participant is on chronic treatment (i.e., two weeks or more) with specific medications known to affect periodontal status (phenytoin or cyclosporine) within one month of baseline visit.
- • 3. Participant knowingly has HIV or Hepatitis.
- • 4. Participant has limited mental capacity or language skills such that simple instructions cannot be followed or information regarding adverse events cannot be provided.
- • 5. Participant on chronic antibiotic therapy or who require antibiotic coverage for periodontal procedures.
- • 6. Participant had a course of periodontal therapy in the preceding 6 month
About University College, London
University College London (UCL) is a leading global research institution renowned for its commitment to advancing healthcare through innovative clinical trials. As a prominent sponsor of clinical research, UCL leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous investigations aimed at improving patient outcomes and addressing pressing medical challenges. The institution fosters collaboration among researchers, healthcare professionals, and industry partners, ensuring that its trials adhere to the highest ethical standards and regulatory guidelines. UCL's dedication to translating scientific discoveries into practical applications underscores its role as a vital contributor to the advancement of medical science and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
John Deanfield, MD
Study Chair
UCL
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials